Retrieval Augmented Generation (RAG) for Natural Language Querying of Immunogenicity Data for Protein Drugs
Open Access
- 21 January 2026
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (2) , 51
Abstract
To evaluate the strengths and limitations of retrieval-augmented generative (RAG) artificial intelligence (AI) for natural language querying of biologics immunogenicity data. The package inserts for drugs approved with biologics license applications (BLA) were retrieved from DailyMed ( https://dailymed.nlm.nih.gov/dailymed/ ). The RAG system integrated natural language processing, retrieval, and large language model (LLM) components. ChatGPT, Gemini, DeepSeek, and Llama were queried with five clinical pharmacology-focused questions on factors influencing anti-drug antibody (ADA) incidence and tolerability, including effects of target protein, administration route, and citrate excipients. Outputs were assessed for relevance, faithfulness, and domain-specific accuracy. The dataset included 663 biologics, of which 206 (31.1%) were monoclonal antibodies. The RAG system retrieved relevant contexts for all queries, but several contexts contained inaccuracies related to the presence of non-antibody protein drugs. All four LLMs generated coherent summaries and identified determinants of ADA incidence, such as drug type, assay methods, and concomitant therapy. All models found that injection-site pain occurred with some protein therapeutics containing citrate excipients, and that evidence for a direct causal role of citrate was mixed. Comparative evaluation showed that LLM outputs were generally relevant and faithful to the source text, with variation in the level of detail and comprehensiveness across models. Domain-specific evaluations indicated that responses accurately identified trends in immunogenicity and highlighted the knowledge gaps. While RAG-based systems can retrieve and synthesize immunogenicity assessments from multiple source documents, significant limitations were noted in this use case. The effectiveness of the retriever can limit RAG performance and warrant refinement. Graphical AbstractKeywords
This publication has 20 references indexed in Scilit:
- Immunogenicity and toxicity of AAV gene therapyFrontiers in Immunology, 2022
- T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020Frontiers in Immunology, 2020
- Immunogenicity of Protein PharmaceuticalsJournal of Pharmaceutical Sciences, 2019
- How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry PerspectiveThe AAPS Journal, 2017
- Lipid-Reduction Variability and Antidrug-Antibody Formation with BococizumabNew England Journal of Medicine, 2017
- Evaluating and Reporting the Immunogenicity Impacts for Biological Products—a Clinical Pharmacology PerspectiveThe AAPS Journal, 2015
- Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicityJournal of Thrombosis and Haemostasis, 2015
- Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfaJournal of Thrombosis and Haemostasis, 2014
- Preclinical Models Used for Immunogenicity Prediction of Therapeutic ProteinsPharmaceutical Research, 2013
- Thrombocytopenia caused by the development of antibodies to thrombopoietinBlood, 2001